The rate of enrolment is what is killing everything atm.
My question as a layman to the Medical Visitors to this Board is:
‘ Is the statement (and I paraphrase) from the Company that they will have treated no more than +/- 7 in Canada by the middle of next year based on Trial strategy dictated by FDA criteria or on an acceptance that there will be no more than this number in the proposed Canadian catchment areas likely to meet the Clinical Protocol and not allocated (by whatever process) to alternative Trials? ’
Thanks.